Immix Biopharma Completes Enrollment In NEXICART-2 Trial, Sets Stage For Topline Results And BLA Submission For NXC-201 In AL Amyloidosis

Immix Biopharma, Inc. announced that enrollment in its NEXICART-2 clinical trial is now complete, meeting company guidance. Topline results from the study are expected in the third quarter of 2026, after which the company plans to submit a Biologics License Application (BLA) and pursue a commercial launch.

Ilya Rachman, MD, PhD, Chief Executive Officer of Immix Biopharma, explained that in AL Amyloidosis, the immune system produces toxic light chains that damage the heart, kidneys, and liver, leading to organ failure and potentially death. He noted that NXC-201, the one-and-done therapy being tested in the NEXICART-2 trial, has shown the ability to eliminate the source of these toxic proteins. If approved, NXC-201 would be the first FDA-approved treatment for relapsed or refractory AL Amyloidosis.

Gabriel Morris, Chief Financial Officer of Immix Biopharma, expressed gratitude to patients, families, caregivers, and investigators for their support, and credited the company’s team for their efforts in advancing the program. He highlighted that the upcoming topline results, building on a positive interim readout presented at ASH 2025, will drive the BLA submission and set the stage for the planned commercial launch.

In addition to announcing the completion of NEXICART-2 enrollment, Immix Biopharma welcomed Richard Graydon, MD, PhD, as Chief Medical Officer. Dr. Graydon, a board-certified hematologist-oncologist with more than 20 years of clinical development experience, has worked at Merck & Co. and Johnson & Johnson, where he led new and supplemental drug applications and biologics license applications for seven approved drugs, including DARZALEX, CARVYKTI, KEYTRUDA, and IMBRUVICA. He received his MD and PhD from Stanford University and completed training at Massachusetts General Hospital.

This leadership addition, combined with the completion of NEXICART-2 enrollment, positions Immix Biopharma to advance NXC-201 toward regulatory approval and provide the first targeted treatment option for patients with relapsed or refractory AL Amyloidosis.